Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy.

Kidney Int Rep · 2026 · PMC13099349 · PMID 42027554

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Lymphocyte Subpopulations Total T-cell counts showed a trend to increase at 5, 6, and 9 months after felzartamab administration compared with baseline, with a transient increase in CD8 + T cells ( Figure 3 , Panel a).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.